OraSure Technologies (OSUR): Progress for Zika & Microbiome, Raising PT - Jefferies

August 30, 2016 8:38 AM EDT
Get Alerts OSUR Hot Sheet
Price: $8.37 -2.11%

Rating Summary:
    11 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade OSUR Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies analyst, Brandon Coulliard, reiterated his Buy rating on shares of OraSure Technologies (NASDAQ: OSUR) after two major positive pipeline developments add greater confidence in near term revenue forecasts & scope for upside to current consensus estimates including: 1) HHS/BARDA contract for rapid Zika test; and 2) third-party study data from Human Longevity (genomics industry KOL) endorsing OSUR's OMNIgene-GUT sample collection device as the de-facto gold-standard for all future microbiome studies.

Additional upcoming catalysts include: 1) Finalization of major HCV test supply contract (~$18M over ~1 yr period); 2) 510(k) submission & approval of rapid Ebola antigen test; 3) Launch of major new consumer genomics testing service (new DNAG customer); 4) possible M&A activities.

The price target increases to $10 from $8.

For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.

Shares of OraSure Technologies closed at $8.66 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment